(12)   **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
14.02.1996 Bulletin 1996/07

(51) Int Cl.6: **C12N 15/18, A61K 38/27,**
C07K 14/475

(21) Application number: **91108943.1**

(22) Date of filing: **31.05.1991**

(54) **Human MK gene and protein sequence**

Menschliches MK Gen und Protein-Sequenz

Gène MK humain et séquence de la protéine

(72) Inventors:
• **Kovesdi, Imre**
Pearl River, New York 10965 (US)
• **Bohlen, Peter**
Peekskill, New York 10566 (US)

(74) Representative:
Wächtershäuser, Günter, Prof. Dr.
D-80331 München (DE)

(56) References cited:
EP-A- 0 326 075

• **BIOCHEMICAL AND BIOPHYSICAL**
RESEARCH COMMUNICATIONS vol. 176, no. 2,
30 April 1991, pages 792-797, New York, US;
J.-I. TSUTSUI et al.: "A New Family of
Heparin-Binding Factors: Strong Conservation
of Midkine (MK) Sequences between the
Human and the Mouse "
• **BIOCHEMICAL AND BIOPHYSICAL**
RESEARCH COMMUNICATIONS vol. 171, no. 2,
14 September 1990, pages 603-609, New York,
US; M. TOMOMURA et al.:
• **THE JOURNAL OF BIOLOGICAL CHEMISTRY**
vol. 265, no. 18, 25 June 1990, pages
10765-10770, Baltimore, US; M.TOMOMURA et
al.: "A Retinoic Acid- responsive Gene, MK,
Found in the Teratocarcinoma System"
• **THE JOURNAL OF BIOLOGICAL CHEMISTRY**
vol. 265, no. 16, 5 June 1990, pages 9441-9443,
Baltimore, US; S. MATSUBARA et al.:
"Structure of a Retinoic Acid-responsive Gene,
MK, Which is Transiently Activated During the
Differentiation of Embryonal Carcinoma Cells
and the Mid-gestation Period of Mouse
Embryogenesis"
• **BIOCHEMICAL AND BIOPHYSICAL**
RESEARCH COMMUNICATIONS vol. 151, no. 3,
30 March 1988, pages 1312-1318, New York, US;
K. KADOMATSU et al.: "cDNA cloning and
Sequencing of a New Gene Intensely
Expressed in Early Differentiation Stages of
Embryonal Carcinoma Cells and In
Mid-Gestation Period of Mouse
Embryogenesis"

EP 0 476 233 B1

Description

This invention relates to a novel DNA sequence for a protein having substantial homology to human heparin binding neurotrophic factor (HBNF). The sequences in question also show a high degree of homology with a previously described murine protein designated as MK1. The homology of MK with these known proteins suggests a similar utility in induction of nerve cell growth and differentiation, as well as nerve cell maintenance and repair. Moreover, the occurrence of the MK gene in teratocarcinoma cells and embryonic development indicates broader utility as a differentiation inducing factor, as well as a tissue maintenance or repair factor.

The protein of the present invention is normally produced in the human brain, but apparently at a different time, developmentally, than HBNF. The human MK protein shows about an 85% homology with the published mouse MK sequence. No recognition of the existence of such a protein in humans has previously been made, although it now appears that MK is a member of a highly conserved gene family which is present in a number of different species.

The gene encoding the human MK protein has been isolated from a cDNA library obtained from human newborn brain stem RNA. The gene has been sequenced and cloned; it is a 366-nucleotide sequence predicting a protein having 121 amino acids.

BACKGROUND OF THE INVENTION

Kadomatsu et al. (Biochem. Biophys. Res. Comm. 151:1312-1318, 1988) isolated and sequenced cDNA from mouse cells, which they referred to as MK1. The corresponding mRNA was said to be abundant in the early stages of mouse embryonic development, but not in later stages. The MK1 protein was suggested as being associated with control of cell differentiation, specifically as a DNA binding protein regulating gene expression. No relationship to any other known protein sequences was found. A subsequent paper (Tomomura et al., J. Biol. Chem. 265:10765-10770, 1990) reported the expression of the MK gene in early stages of embryonal carcinoma cell differentiation, and also noted the occurrence of three distinct classes of cDNA clones, referred to as MK1, MK2 and MK3. Kadomatsu et al. (J. Cell. Biol. 110:607-616, 1990) suggested MK may play a fundamental role in the differentiation of a variety of cells, and that it may be involved in the generation of epithelial tissues and in the remodeling of mesoderm.

The mouse MK1 sequence has now been found to have a high degree of homology in the group of proteins known as heparin-binding neurotrophic factors (HBNFs); the nucleotide sequence encoding the latter proteins has been disclosed in applicants' copending and cofiled Serial No. 07/568,574. The HBNF proteins were originally disclosed as HBBMS, in EP 325076. It has now been unexpectedly discovered that a gene corresponding to the mouse MK sequence is also found in human brain. The present invention provides the entire sequence of the gene encoding the human protein, as well as the predicted amino acid sequence of the mature protein, cloning and expression vectors, and host cells capable of expressing the gene and producing pure MK protein. In view of the strong homology between the MK proteins and HBNF, it is likely that these constitute a family of genes and proteins having developmental significance.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 (See also Sequence Listing 1). Nucleotide and amino acid sequence of the human MK gene. Boldfaced amino acids represent the predicted protein presequence, the arrow represents the predicted N-terminus of the mature protein, and the two peptide sequences corresponding to primers 1 and 2 used to amplify the mouse genomic DNA probe are underlined. The two polyadenylation sequences near the 3' end of the gene are underlined.

Figure 2 shows a comparison of the mature protein region of human HBNF (See also Sequence Listing 3) and MK nucleotide and deduced amino acid sequence. Identical amino acids are indicated in bold letters. Identities in the two nucleotide sequences are indicated by stars (*).

Figure 3 shows a nucleotide sequence and deduced amino acid sequence of human and mouse MK (See also Sequence Listing 2). Differences in the two nucleotide sequences are indicated by stars (*). Differences in the amino acids are indicated in bold letters. Amino acids used in the mouse genomic PCR primer design are underlined.

Figure 4. Bacterial Expression of human recombinant HBNF and MK proteins. Cell lysates are from bacterial cultures containing the expression plasmids pETHH8 or pETMH2. Lanes 1 and 2, lysates from uninduced and IPTG-induced cultures containing pETMH2. Lane 3, purified recombinant MK protein. Lanes 4 and 5, uninduced and induced cultures containing pETHH8. Lane 6, purified recombinant HBNF protein. Protein standards are from BRL.

Figure 5. Neurite outgrowth assays of purified recombinant HBNF and MK proteins. Purified proteins are assayed on 18-day fetal rat neurons at concentrations indicated. (A) Neuronal cells with no added protein. (b) Bovine brain-derived HBNF protein (160 ng/ml). (C) Purified recombinant human HBNF protein (150 ng/ml). (d) Purified recombinant human MK protein (150 ng/ml).

Figure 6 shows (a) Expression of HBNF gene during rat embryogenesis. From each tissue 20 ug total RNA was applied per lane and hybridized with a ^{32}P-labeled human HBNF cDNA probe. Tissues used in the RNA isolation were

total embryo proper for E8 and E10, heads for E12 and E14, total brain for E16, E18, E20, P2 and Adult; (b) expression of MK gene during rat embryogenesis. Same northern blot as in (a) hybridized with a ^{32}P-labeled human MK cDNA probe.

Figure 7. Gene expression of HBNF and MK in the adult rat brain. RNA extracted from various brain regions of 2-month-old rats was subjected to northern analysis (10 μg/lane of RNA; Lane 1 - total brain, 2 - cortex, 3 - hippocampus, 4 - cerebellum, 5 - caudate nucleus, 6 - midbrain + hypothalamus, 7 - brain stem). The resulting blot was hybridised consecutively to probes for HBNF, MK and β-actin.

Figure 8. Retinoic acid-induced expression of HBNF and MK genes in NT2/D1 cells. NT2/D1 cells were treated with varying concentrations of RA, grown for 9 days, and RNA extracted. (A) For each RA concentration of 10 μg of RNA was used in northern analysis. The resulting blot was consecutively hybridized with HBNF, MK and β-actin probes. (B) Hybridization signals obtained in (A) for HBNF (black) and MK (hatched) were measured by densitometry and normalised to the β-actin signals.

DETAILED DESCRIPTION OF THE INVENTION

The DNA sequence encoding human MK is cloned by isolating a combination of polymerase chain reaction (PCR) and screening of a cDNA library derived from newborn human brain stem. The human HBNF sequence is used as the starting point for designing oligonucleotides for a PCR amplification reaction; this sequence is shown in Figure 2. Specific oligonucleotides are designed to the regions most conserved between HBNF and the published mouse MK1 DNA sequence. These oligonucleotides are used as primers in a polymerase chain reaction (PCR) on mouse genomic DNA. The expected 150 base pair product is cloned in an appropriate vector and the sequence determined. This clone is used as a probe for screening a human brain cDNA library to identify the human MK equivalent gene. A single clone is isolated, subcloned and sequenced. The sequence of one of these clones is shown in Figure 1, and accounts for 790 nucleotides of the estimated 1100 nucleotides of mature human MK mRNA. The nucleotide sequence is subsequently confined in additional shorter-length MK clones, which are found to contain different overlapping fragments of the original clone. The sequence of the MK cDNA includes two polyadenylation signals and a poly A tail (Figure 1). The original isolated clone has an open reading frame with a coding region beginning at nucleotide 22 and defining a 143 residue protein. The N-terminal sequence is highly hydrophobic and has the characteristics of a signal peptide (Von Heijne, J. Mol. Biol. 184:99-105, 1985). On the basis of the criteria for signal peptide structures set forth by Von Heijne (id; Nucl. Acid Res. 14:4683-4690, 1986) and comparisons with mouse MK and human HBNF sequences, it is assumed that signal peptide cleavage occurs between amino acid residues 22 (Ala) and 23 (Lys), thus giving rise to a mature MK polypeptide of 121 residues in length.

As shown in Figure 3, a comparison of the human MK deduced amino acid sequence with the mouse MK protein sequence indicates a difference of only about 15%. Most of these changes are conservative. The homology between MK and HBNF, shown in Figure 2, indicates a homology of 50%, increasing to 63% when conserved amino acid changes are included. Ten Cysteines which are present in both proteins are perfectly aligned, suggesting similar structures.

To provide a source of the mature MK protein free of contaminating eukaryotic proteins, cDNA clones isolated above are used as templates for PCR amplification with primers designed to place a methionine codon immediately 5' of the N-terminal lysine residue of the mature proteins. The amplified product is cloned into a modified form of the expression vector pET-3a (Studier, et al., 1990), and the resulting plasmid pETMH2 is transformed into E. coli strain BL21 LysS. Protein extracts of IPTG-induced pETMH2-containing bacteria express a major protein band migrating at approximately 16.5 kDa (Figure 4, Lane 2). Uninduced culture (Lane 1, pETMH2-containing bacteria) contains much less of the protein as judged by SDS-PAGE band intensities. Recombinant MK protein is purified from IPTG-induced bacterial cultures by heparin affinity chromatography (Figure 4, Lane 3) and its N-terminal sequence and amino acid compositions confirmed.

Homology between the human and published mouse MK DNA and the deduced protein sequences show a lower level of conservation than a similar evolutionary comparison of HBNF (Figure 3). Using a putative N-terminus from the mature MK protein deduced from homology with HBNF, 86% amino acid identity is observed including a three amino acid deletion in the mouse sequence. Both HBNF and MK are expressed in brain but their temporal and spatial regulation differs. Preliminary in situ hybridisation showed distinct patterns of expression for the two messages. Northern hybridization analysis of mouse RNA from the adult tissues examined indicates that only brain expressed a 1650-nucleotide HBNF message (Figure 6). This is consistent with previous investigations on the expression characteristics of the HBNF protein which show it is present in the brain (EP 326 075, Rauvala, EMBO J. 8:2933-2941, 1989). Recently, HBNF protein was also isolated from bovine uterus (Milner et al. Biochem. Biophys. Res. Comm. 165:1096-1103, 1989). These initial experiments indicated that MK is not expressed in any adult tissue examined (Figure 6). However, subsequent experiments indicate that MK mRNA is detectable in two regions of the adult brain, the caudate nucleus and the brain stem (Figure 7). Based on the significantly longer exposure times needed to see these bands in adult RNA as compared to equivalent amounts of embryonic RNA, it appears that MK RNA is expressed at minimal levels in the adult.

The temporal expression of both genes is evaluated by northern blot analysis with total rat RNA from various developmental stages. Hybridization with an HBNF probe indicates a gradual increase of message throughout develop-

ment, with the highest level occurring in the adult brain (Figure 6a). Hybridization of the same blot with an MK probe indicates that only 12-, 14- and 16-day embryonic tissues contained the measage. The most abundant presence of MK message appears to be in the embryonic day 12 stage (Figure 6b). These results are in general agreement with the in situ hybridisation studies of Kadomatsu (supra). However, contrary to the findings of Kadomatsu, we were unable to detect MK mRNA expression in kidney tissue. Studies of HBNF protein in rat brains suggest that the highest level occurs in postnatal day-7 pups. This level reflects a ten-fold difference when compared to 56-day old animals (Rauvala, supra).

The human embryonal carcinoma (EC) cell line NT2/D1 can be induced to differentiate at concentrations of retinoic acid (RA) varying from 0.01 to 10 μM, with the proportion of differentiating EC cells ranging from 50% at 0.01 μM RA (Simeone, et al., Nature 346:763-766, 1990) to greater than 99% at 1 and 10 μM RA (Andrews, Dev. Biol. 103:285-293, 1984). The expression of MK and HBNF during differentiation of NT2/D1 is studied, at concentrations ranging from 0.01 to 10 μM. After nine days of exposure to RA, total RNA was extracted from cells and probed for gene expression by northern analysis. Expression of both genes followed a similar pattern (Figure 8). Levels of mRNA expression remained at a steady background level with 0.1-0.5 μm RA, rapidly increased between 0.1 and 0.5 μM RA, and maintained this level at concentrations up to and including 10 μM RA. When RNA hybridization signals were normalized to a control β-actin probe, the maximum increases were calculated to be 6-fold for HBNF and 11-fold for MK (Figure 8). These results are comparable to those observed for MK during retinoic acid induction of the mouse EC cell line, HM-1 (Kadomatsu et al.,supra). In this cell line, MK gene expression was induced 8-10 fold above background.

Recombinant HBNF and MK proteins are assayed for the ability to stimulate neurite outgrowth of 18-day fetal rat brain neurons. Both bacterially-derived proteins showed neurite outgrowth-promoting activity similar to that of native bovine HBNF (Figure 5). The recombinant MK protein is also assayed for mitogenic activity on adult bovine aortic endothelial cells and NIH 3T3 fibroblasts. MK protein shows no mitogenic activity on these cells. However, conditioned medium from MK-transfected L cells has been reported to be mitogenic from PC12 cells by Tomomura (Biochem. Biophys. Res. Comm. 171: 603, 609, 1990).

The findings of the present invention thus indicate that HBNF and MK are members of a highly conserved gene family. Furthermore, the gene expression data implies that these genes function in the proliferation, maintenance and/or developmental differentiation of tissue and, in particular, nerve tissue.

The following examples illustrate the cloning and expression of the MK gene in a T7 RNA polymerase expression system. However, although this T7 expression system is quite efficient, it is to be understood that this is not the only means by which MK can be produced recombinantly. Production of MK can be achieved by incorporation of the MK gene into any suitable expression vector and subsequent transformation of an appropriate host cell with the vector; alternately the transformation of the host cells can be achieved directly by naked DNA without the use of a vector. Production of MK by either eukaryotic cells or prokaryotio cells is contemplated by the present invention. Examples of suitable eukaryotic cells include mammalian cells, plant cells, yeast cells and insect cells. Similarly, suitable prokaryotic hosts, in addition to E. Coli, include Bacillus subtilis.

Other suitable expression vectors may also be employed and are selected based upon the choice of host cell. For example, numerous vectors suitable for use in transforming bacterial cells are well known. For example, plasmids and bacteriophages, such as λ phage, are the most commonly used vectors for bacterial hosts, and for E. Coli in particular. In both mammalian and insect cells, virus vectors are frequently used to obtain expression of exogenous DNA. In particular mammalian cells are commonly transformed with SV40 or polyoma virus; and insect cells in culture may be transformed with baculovirus expression vectors. Yeast vector systems include yeast centromere plasmids, yeast episomal plasmids and yeast integrating plasmids.

It will also be understood that the practice of the invention is not limited to the use of the exact sequence of the MK gene as defined in Figure 1. Modifications to the sequence, such as deletions, insertions, or substitutions in the sequence which product silent changes in the resulting protein molecule are also contemplated. For example, alterations in the gene sequence which result in the production of a chemically equivalent amino acid at a given site are contemplated; thus, a codon for the amino acid alanine, a hydrophobic amino acid, can readily be substituted by a codon encoding another hydrophobic residue, such as glycine, or may be substituted with a more hydrophobic residue such a valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule frequently do not alter protein activity, as these regions are usually not involved in biological activity. It may also be desirable to eliminate one or more of the cysteines present in the sequence, as the presence of cysteines may result in the undesirable formation of multimers when the protein is produced recombinantly, thereby complicating the purification and crystallization processes. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Therefore, where the phrase "MK DNA sequence" or "MK gene" is used in either the specification or the claims, it will be understood to encompass all such modifications and variations which result in the production of a biologically equivalent MK protein. In particular, the invention contemplates those DNA sequences which are sufficiently duplicative of the sequence of

Figure 1 so as to permit hybridisation therewith under standard high stringency southern hybridisation conditions, such as those described in Maniatis et al., (Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory, 1982). The MK protein is strongly homologous to the HBNF protein and, like HBNF, stimulates induction of neurite outgrowth. MK is, therefore, proposed as a neurotrophic agent. As such, the MK proteins are useful both in vivo and in vivo, in growth, maintenance and repair of nerve cells of the peripheral and central nervous systems. An example of in vitro application is in maintenanae of embryonic brain implants which are now proposed for use in treatment of Parkinson's disease.

In view of the apparent role in differentiation, the MK protein is also proposed as a general tissue differentiation, maintenance and repair factor. In particular, MK may be useful in treatment of tumor cells to induce reversion to a differentiated phenotype.

In vivo administration of MK is significantly simplified by the discovery of the gene sequence, particularly in treatment of central or peripheral nervous system injury. The identification of the gene and its sequence permit construction of transgenic cells such as fibroblasts, monocytes, or macrophages, which may be engineered to permit expression of the MK gene and used as an implant for treatment of neurodegenerative disorders, peripheral nerve repair following surgery, or any conditions in which enhancement of nerve cell growth and/or repair would be desirable.

Moreover, the therapeutic use of MK is not limited to treatment of humans alone. In fact, in view of the conserved nature of this protein among distantly related species, administration of MK in any form may be beneficial for veterinary application as well. Therapeutic compositions comprise MK in an amount effective to induce the desired biological activity in combination with a pharmaceutically acceptable liquid or solid carrier. Alternately, the composition comprises a pharmaceutically acceptable aggregation of compatible transgenic cells capable of expressing MK in vitro, as an implant for peripheral and central nervous system repairs or differentiation treatment.

EXAMPLE

CLONING AND SEQUENCING OF THE MK GENE

The published mouse MK protein amino acid sequence was used to create specific oligonucleotides to be used as primers in a polymerase chain reaction. Mouse genomic DNA was isolated from C57 Black/6J mice, as described in Maniatis et al. supra.

A sense primer is made to the amino acid sequence: CNWKKEFG (Figure 1) starting with a HindIII restriction site and comprised of the DNA sequence:

5'GGAATTCGGTCTCCTGGCACTGGGCAGT-3'.

The PCR reaction is carried out on the complementary DNA template with a minute annealing at 50°C, 2 minutes extension at 72°C and 1 minute denaturation at 94°C for 30 cycles using Taq polymerase (USB Corp.)

The 150 base pair mouse MK PCR product is cloned into Blue Scribe (+) vector (Stratagene) and used as a probe in screening a newborn brain stem and basal ganglia λ gt 11 cDNA library (Kamhols, PNAS USA 83:4962-54966, 1986). A single putative clone containing the MK sequence is isolated and subcloned into the EcoRI site of Blue Scribe (+) and sequenced by the dideoxynucleotide chain termination method (Sanger et al. PNAS USA 74:5463-5467, 1988) The sequence of the MK gene, as well as the predicted amino acid sequence is presented in Figure 1. Comparison with the mouse MK sequence shows a 41 nucleotide difference, including the three codon deletion in the mouse sequence.

EXPRESSION OF RECOMBINANT HUMAN MK

The isolated clone noted above, referred to as pMKHC2 is used as a template for PCR amplification with primers designed to place a methionine codon and an Nde I restriction site immediately 5' to the N-terminal lysine. The purified PCR product is cloned into a derivative of the expression vector pET-3a, which is modified by the deletion of the 1400 bp SalI/PvuII fragment and insertion of an f1 origion of replication into the EcoRI site. After sequencing the insert to confirm the fidelity of the PCR amplification, the plasmid (named pETMH2; also previously referred to as pETMKHC2) is transformed into strain BL21 lysS and induced for protein production with IPTG as described (Studier et al., supra). Pellets from one ml culture are resuspended in 100 µl of SDS buffer (Laemmli, Nature 227:680-685, 1970) and 2.5 µl run on a 15 acrylamide SDS-PAGE gel. The gel is stained with coomassie blue. Recombinant MK is purified from bacterial extract on heparin sepharose CL-6B (Pharmacia) resin in 10 mM Tris, pH 7.0 and eluted at 1-1.13 M NaCl. Further purification is achieved on Mono S (Pharmacia) columns in 50 mM sodium phosphate, pH 6.8, with increasing salt concentration from 0 to 1 M NaCl. Purified protein is eluted at .6 M Nacl.

NEURITE OUTGROWTH ASSAYS

Brains from 18-day fetal rats are removed under sterile conditions and dispersed to single cells in DMEM containing 10% FCS using a sterile 5 ml syringe. The cell suspension as adjusted to 5×10^5 cellS/ml and plated onto tissue culture dishes that are precoated with 50 µg/ml poly-L-lysine for 30 minutes at room temperature (Rauvala and Pihlaskari, J. Biol. Chem. 262:16625-16635, 1987). Cultures are incubated for 24 hours at 37°C in 10% CO_2, after which the media is changed to DMEM containing 1 mg/ml BSA, and HBNF or MK proteins are added at indicated concentrations. After a further one-day incubation, neurite outgrowth activity is determined by visual examination of cells for extended out-growth/processes as compared to controls. As shown in Figure 5D, purified recombinant MK is capable of stimulating neurite outgrowth to substantially the same extent as recombinant HBNF and bovine brain derived HBNF.

GROWTH AND RETINOIC ACID INDUCTION OF THE HUMAN NT2/D1 CELLS

The human embryonal carcinoma cell line NT2/D1 is grown as described previously (Andrews, Dev. Biol. 103:285-293, 1984). For retinoic acid induction, cells are grown and resuspended in DMEM medium containing 10% bovine calf serum and resuspended in DMEM medium containing 10% bovine calf serum (Hyclone Laboratories, Inc.) at a density of 5×10^5 cells per 100 mm dish. Varying concentrations of all-trans retinoic acid in dimethyl sulfoxide (10 µl) is added, and cells are incubated for 9 days. Fresh medium and RA are added at days 4 and 8. Plates are washed once with phosphate buffered saline, and RNA extracted as described above. Figure 8 shows a graphic representation of the levels of both HBNF and MK produced in response to varying levels of retinoic acid concentration. Since NT2/D1 cells induced with RA have been suggested as providing a model system for studies of neuronal differentiation (Lee and Andrews, J. Neurosci. 6:514-521, 1986), the increase in induction of HBNF and MK genes in this system indicates a possible role in neuronal cell development.

DEPOSIT OF BIOLOGICAL MATERIALS

E. coli strain M 1061 harboring pMKHC2 and E. coli strain BL2T LysS harboring pETMH2 have been deposited in the culture collections of American cyanamid Company, Lederle Laboratories, Pearl River, New York, and with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, under accession number ATCC 68384, on August 13, 1990 and accession number 68401, on September 17, 1990, respectively.

Sequence ID No.:   1

Sequence Type: Nucleic Acid and Amino Acid

Sequence Length: 799 Base Pairs   143 Amino Acids

Strandedness: Single

Topology: Linear

Original Source Organism: Human

Properties: Human MK Gene and Protein Sequence

```
CGGGCGAAGC AGCGCGGGCA GCGAG                                     25

ATG CAG CAC CGA GGC TTC CTC CTC CTC ACC CTC CTC               61
Met Gln His Arg Gly Phe Leu Leu Leu Thr Leu Leu
 1               5                   10

GCC CTG CTG GCG CTC ACC TCC GCG GTC GCC AAA AAG               97
Ala Leu Leu Ala Leu Thr Ser Ala Val Ala Lys Lys
          15                  20

AAA GAT AAG GTG AAG AAG GGC GGC CCG GGG AGC GAG              133
Lys Asp Lys Val Lys Lys Gly Gly Pro Gly Ser Glu
25               30                  35

TGC CGT GAG TGG GCC TGG GGG CCC TGC ACC CCC AGC              169
Cys Arg Glu Trp Ala Trp Gly Pro Cys Thr Pro Ser
              40                  45

AGC AAG GAT TGC GGC GTG GGT TTC CGC GAG GGC ACC              205
Ser Lys Asp Cys Gly Val Gly Phe Arg Glu Gly Thr
          50                  55                  60

TGC GGG GCC CAG ACC CAG CGC ATC CGG TGC AGG GTG              241
Cys Gly Ala Gln Thr Gln Arg Ile Arg Cys Arg Val
                  65                  70

CCC TGC AAC TGG AAG AAG GAG TTT GGA GCC GAC TGC              277
Pro Cys Asn Trp Lys Lys Glu Phe Gly Ala Asp Cys
              75                  80

AAG TAC AAG TTT GAG AAC TGG GGT GCG TGT GAT GGG              313
Lys Tyr Lys Phe Glu Asn Trp Gly Ala Cys Asp Gly
    85                  90                  95

GGC ACA GGC ACC AAA GTC CGC CAA GGC ACC CTG AAG              349
Gly Thr Gly Thr Lys Val Arg Gln Gly Thr Leu Lys
              100                 105
```

```
AAG GCG CGC TAC AAT GCT CAG TGC CAG GAG ACC ATC
Lys Ala Arg Tyr Asn Ala Gln Cys Gln Gly Thr Ile          385
    110                 115                 120

CGC GTC ACC AAG CCC TGC ACC CCC AAG ACC AAA GCA
Arg Val Thr Lys Pro Cys Thr Pro Lys Thr Lys Ala          421
                125                 130

AAG GCC AAA GCC AAG AAA GGG AAG GGA AAG GAC TAG
Lys Ala Lys Ala Lys Lys Gly Lys Gly Lys Asp Xaa          457
            135                 140

ACGCCAAGCC TGGATGCCAA GGAGCCCCTG GTGTCACATG                497

GGGCCTGGCC ACGCCCTCCC TCTCCCAGGC CCGAGATGTG                537

ACCCACCAGT GCCTTCTGTC TGCTCGTTAG CTTTAATCAA                577

TCATGCCCTG CCTTGTCCCT CTCACTCCCC AGCCCCACCC                617

CTAAGTGCCC AAAGTGGGGA GGGACAAGGG ATTCTGGGAA                657

GCTTGAGCCT CCCCCAAAGC AATGTGAGTC CCAGAGCCCG                697

CTTTTGTTCT TCCCCACAAT TCCATTACTA AGAAACACAT                737

CAAATAAACT GACTTTTTCC CCCCAATAAA AGCTCTTCTT                777

TTTTAATATA AAAAAAAAAA AA                                   799
```

Sequence ID No.: 2

Sequence Type: Nucleic Acid and Amino Acid

Sequence Length: 354 Base Pairs   118 Amino Acids

Strandedness: Single

Topology: Linear

Original Source Organism: Mouse

Properties: Mouse MK Gene and Protein Sequence

```
AAA AAA AAA GAG AAG GTG AAG AAG GGC AGC GAG TGT        36
Lys Lys Lys Glu Lys Val Lys Lys Gly Ser Glu Cys
 1               5                   10

TCG GAG TGG ACC TGG GGG CCC TGC ACC CCC AGC AGC        72
Ser Glu Trp Pro Trp Gly Pro Cys Thr Pro Ser Ser
         15                  20

AAG GAC TGC GGC ATG GGC TTC CGC GAG GGT ACC TGT       108
Lys Asp Cys Gly Met Gly Phe Arg Glu Gly Thr Cys
 25              30                      35

GGG GCC CAG ACC CAG CGC GTC CAT TGC AAG GTG CCC       144
Gly Arg Gln Thr Gln Arg Val His Cys Lys Val Pro
            40                  45

TGC AAC TGG AAG AAG GAA TTT GGA GCC GAC TGC AAA       180
Cys Asn Trp Lys Lys Glu Phe Gly Ala Asp Cys Lys
        50                  55                  60

TAC AAG TTT GAG AGC TGG GGG GCG TGT GAT GGG AGC       216
Tyr Lys Phe Glu Ser Trp Gly Ala Cys Asp Gly Ser
                65                  70

ACT GGC ACC AAA GCC CGC CAA GGG ACC CTG AAG AAG       252
Thr Gly Thr Lys Ala Arg Gln Gly Thr Leu Lys Lys
            75                  80

GCG CGG TAC ACT GCC CAG TGC CAG GAG ACC ATC CGC       288
Ala Arg Tyr Thr Ala Gln Cys Gln Glu Thr Ile Arg
 85                  90                  95

GTG ACT AAG CCC TGC ACC TCC AAG ACC AAG TCA AAG       324
Val Thr Lys Pro Cys Thr Ser Lys Thr Lys Ser Lys
            100                 105

ACC AAA GCC AAG AAA GGA AAA GGA AAG GAC              354
Thr Lys Ala Lys Lys Gly Lys Gly Lys Asp
    110             115         118
```

Sequence ID No.: 3

Sequence Type: Nucleic Acid and Amino Acid

Sequence Length: 411 Base Pairs 136 Amino Acids

Strandedness: Single

Topology: Linear

Original Source Organism: Human

Properties: Human HBNF Gene and Protein Sequence

```
GGG AAG AAA GAG AAA CCA GAA AAA AAA GTG AAG AAG          36
Gly Lys Lys Glu Lys Pro Glu Lys Lys Val Lys Lys
 1               5                   10

TCT GAC TGT GGA GAA TGG CAG TGG AGT GTG TGT GTG          72
Ser Asp Cys Gly Glu Trp Gln Trp Ser Val Cys Val
        15                  20

CCC ACC AGT GGA GAC TGT GGG CTG GGC ACA CGG GAG          108
Pro Thr Ser Gly Asp Cys Gly Leu Gly Thr Arg Glu
 25                  30                      35

GGC ACT CGG ACT GGA GCT GAG TGC AAG CAA ACC ATG          144
Gly Thr Arg Thr Gly Ala Glu Cys Lys Gln Thr Met
                40              45

AAG ACC CAG AGA TGT AAG ATC CCC TGC AAC TGG AAG          180
Lys Thr Gln Arg Cys Lys Ile Pro Cys Asn Trp Lys
        50              55                  60

AAG CAA TTT GGC GCG GAG TGC AAA TAC CAG TTC CAG          216
Lys Gln Phe Gly Ala Glu Cys Lys Tyr Gln Phe Trp
                65              70

GCC TGG GGA GAA TGT GAC CTG AAC ACA GCC CTG AAG          252
Ala Trp Gly Glu Cys Asp Leu Asn Thr Ala Leu Lys
            75              80

ACC AGA ACT GGA AGT CTG AAG CGA GCC CTG CAC AAT          288
Thr Arg Thr Gly Ser Leu Lys Arg Ala Leu His Asn
 85                  90                  95

GCC GAA TGC CAG AAG ACT GTC ACC ATC TCC AAG CCC          324
Ala Glu Cys Gln Lys Thr Val Thr Ile Ser Lys Pro
                100                 105

TGT GGC AAA CTG ACC AAG CCC AAA CCT CAA GCA GAA          360
Cys Gly Lys Leu Thr Lys Pro Lys Pro Gln Ala Glu
        110                 115                 120
```

```
TCT AAG AAG AAG AAA AAG GAA GGC AAG AAA CAG GAG          396
Ser Lys Lys Lys Lys Lys Glu Gly Lys Lys Gln Glu
            125                     130

AAG ATG CTG GAT TAA                                      411
Lys Met Leu Asp Xaa
135 136
```

Claims

1. A purified and isolated DNA having the MK sequence depicted in Figure 1 encoding a human MK protein, or a portion thereof, which encodes a biologically active MK protein.

2. A DNA which is hybridizable with the MK sequence depicted in Figure 1 under standard high stringency conditions.

3. A method for production of pure human MK protein or a portion thereof which comprises transforming a host cell with the DNA of Claim 1 and culturing the host cell under conditions which permit expression of the DNA by the host cell.

4. An expression vector comprising the DNA of Claim 1.

5. A transgenic cell comprising the DNA of Claim 1.

6. The cell of Claim 5 which is deposited with the American Type Culture Collection as ATCC 68384.

7. A purified isolated MK protein having a sequence depicted in Figure 1 and homologues or fragments thereof which retain MK biological activity.

8. A therapeutic composition comprising an effective amount of the MK protein of Claim 7 in combination with a pharmaceutically acceptable carrier.

9. A method of maintaining or promoting growth of nerve cells in vitro which comprises culturing the cells in the presence of an effective amount of the protein of Claim 7.

10. A method for inducing differentiation of undifferentiated cells which comprises applying to the cells an effective amount of the protein of Claim 7.

11. Use of the cells of Claim 5 for preparing a composition for repairing or treating damaged nerve cells in vivo which comprises an effective amount of compatible transgenic cells capable of expressing an MK protein.

Claims for the following Contracting States :ES, GR

1. A method for production of pure human MK protein or a portion thereof which comprises transforming a host cell with a purified and isolated DNA having the MK sequence depicted in Figure 1 encoding a human MK protein, or a portion thereof, which encodes a biologically active MK protein, and culturing the host cell under conditions which permit expression of the DNA by the host cell.

2. A method according to claim 1, wherein said DNA is hybridizable with the MK sequence depicted in Figure 1 under standard high stringency conditions.

3. A method according to claim 1, wherein the protein obtainable comprises the sequence depicted in Figure 1 and

homologues or fragments thereof which retain MK biological activity.

4. A method of maintaining or promoting growth of nerve cells in vitro which comprises culturing the cells in the presence of an effective amount of a protein obtainable according to the process of any of claims 1 to 3.

5. A method for inducing differentiation of undifferentiated cells which comprises applying to the cells an effective amount of a protein obtainable according to the process of any of claims 1 to 3.

6. An expression vector comprising a purified and isolated DNA having the MK sequence depicted in Figure 1 encoding a human MK protein, or a portion thereof, which encodes a biologically active MK protein.

7. A transgenic cell comprising a purified and isolated DNA having the MK sequence depicted in Figure 1 encoding a human MK protein, or a portion thereof, which encodes a biologically active MK protein.

8. A cell according to claim 7, which is deposited with the American Type Culture Collection as ATCC 68384.

9. Use of the cells of claim 7 for preparing a composition for repairing or treating damaged nerve cells in vivo which comprises an effective amount of compatible transgenic cells capable of expressing an MK protein.

10. A process for producing a therapeutic composition which comprises the mixture of an effective amount of a protein obtainable according to the process of any of claims 1 to 3 with a pharmaceutically acceptable carrier.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Gereinigte und isolierte DNA mit der in Figur 1 dargestellten MK-Sequenz, die für ein menschliches MK-Protein kodiert, oder ein Teil derselben, der für ein biologisch aktives MK-Protein kodiert.

2. DNA, die mit der in Figur 1 dargestellten MK-Sequenz unter hochstringenten Standard-Bedingungen hybridisierbar ist.

3. Verfahren zur Herstellung von reinem menschlichem MK-Protein oder einem Teil desselben, umfassend das Transformieren einer Wirtszelle mit der DNA nach Anspruch 1 und das Kultivieren der Wirtszelle unter Bedingungen, die die Expression der DNA durch die Wirtszelle gestatten.

4. Expressionsvektor, der die DNA nach Anspruch 1 umfaßt.

5. Transgene Zelle, die die DNA nach Anspruch 1 umfaßt.

6. Zelle nach Anspruch 5, die bei der American Type Culture Collection als ATCC 68384 hinterlegt ist.

7. Gereinigtes, isoliertes MK-Protein mit einer in Figur 1 dargestellten Sequenz und Homologe oder Fragmente desselben, die die biologische MK-Aktivität beibehalten.

8. Therapeutische Zusammensetzung, die eine wirksame Menge des MK-Proteins nach Anspruch 7 in Kombination mit einem pharmazeutisch annehmbaren Träger umfaßt.

9. Verfahren zur Beibehaltung oder Förderung des Wachstums von Nervenzellen in vitro, umfassend das Kultivieren der Zellen in Anwesenheit einer wirksamen Menge des Proteins nach Anspruch 7.

10. Verfahren zur Induzierung einer Differenzierung von undifferenzierten Zellen, umfassend das Versetzen der Zellen mit einer wirksamen Menge des Proteins nach Anspruch 7.

11. Verwendung der Zellen nach Anspruch 5 zur Herstellung einer Zusammensetzung zur Wiederherstellung oder Behandlung von beschädigten Nervenzellen in vivo, welche eine wirksame Menge an kompatiblen transgenen Zel-

len umfaßt, die ein MK-Protein exprimieren können.

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung von reinem menschlichem MK-Protein oder einem Teil desselben, umfassend das Transformieren einer Wirtszelle mit einer gereinigten und isolierten DNA mit der in Figur 1 dargestellten MK-Sequenz, die für ein menschliches MK-Protein kodiert, oder einem Teil derselben, der für ein biologisch aktives MK-Protein kodiert, und das Kultivieren der Wirtszelle unter Bedingungen, die die Expression der DNA durch die Wirtszelle gestatten.

2. Verfahren nach Anspruch 1, bei dem die DNA mit der in Figur 1 dargestellten MK-Sequenz unter hochstringenten Standard-Bedingungen hybridisierbar ist.

3. Verfahren nach Anspruch 1, bei dem das erhältliche Protein die in Figur 1 dargestellte Sequenz und Homologe oder Fragmente derselben umfaßt, die eine biologische MK-Aktivität beibehalten.

4. Verfahren zur Beibehaltung oder Förderung des Wachstums von Nervenzellen in vitro, umfassend das Kultivieren der Zellen in der Anwesenheit einer wirksamen Menge eines Proteins, das durch das Verfahren nach irgendeinem der Ansprüche 1 bis 3 erhältlich ist.

5. Verfahren zur Induzierung der Differenzierung von undifferenzierten Zellen, umfassend das Versetzen der Zellen mit einer wirksamen Menge eines Proteins, das nach dem Verfahren nach irgendeinem der Ansprüche 1 bis 3 erhältlich ist.

6. Expressionsvektor, umfassend eine gereinigte und isolierte DNA mit der in Figur 1 dargestellten MK-Sequenz, die für ein menschliches MK-Protein kodiert, oder einen Teil derselben, der für ein biologisch aktives MK-Protein kodiert.

7. Transgene Zelle, umfassend eine gereinigte und isolierte DNA mit der in Figur 1 dargestellten MK-Sequenz, die für ein menschliches MK-Protein kodiert, oder einen Teil derselben, der für ein biologisch aktives MK-Protein kodiert.

8. Zelle nach Anspruch 7, die bei der American Type Culture Collection als ATCC 68384 hinterlegt ist.

9. Verwendung der Zellen nach Anspruch 7 zur Herstellung einer Zusammensetzung zur Wiederherstellung oder Behandlung von beschädigten Nervenzellen in vivo, welche eine wirksame Menge an kompatiblen transgenen Zellen umfaßt, die ein MK-Protein exprimieren können.

10. Verfahren zur Herstellung einer therapeutischen Zusammensetzung, umfassend das Mischen einer wirksamen Menge eines nach dem Verfahren von irgendeinem der Ansprüche 1 bis 3 erhältlichen Proteins mit einem pharmazeutisch annehmbaren Träger.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. ADN purifié et isolé, ayant la séquence de MK décrite dans la figure 1, codant pour une protéine MK humaine, ou une portion de celle-ci, qui code pour une protéine MK biologiquement active.

2. ADN pouvant être hybridé à la séquence MK décrite dans la Figure 1 dans des conditions hautement stringentes standard.

3. Procédé de production de protéine MK humaine pure ou d'une portion de celle-ci, qui comprend la transformation d'une cellule hôte par l'ADN de la revendication 1 et la culture de la cellule hôte dans des conditions qui permettent l'expression de l'ADN par la cellule hôte.

4. Vecteur d'expression comprenant l'ADN de la revendication 1.

5. Cellule transgénique comprenant l'ADN de la revendication 1.

6. Cellule de la revendication 5, qui est déposée à l'American Type Culture Collection sous le numéro d'accession ATCC 68384.

7. Protéine MK isolée purifiée ayant une séquence décrite dans la figure 1, et homologues ou fragments de celle-ci qui conservent l'activité biologique de MK.

8. Composition thérapeutique comprenant une quantité efficace de la protéine MK de la revendication 7 en combinaison avec un véhicule acceptable du point de vue pharmaceutique.

9. Procédé d'entretien ou d'activation de la croissance de cellules nerveuses in vitro qui comprend la culture des cellules en présence d'une quantité efficace de la protéine selon la revendication 7.

10. Procédé d'induction de la différentiation de cellules indifférenciées qui comprend l'application aux cellules d'une quantité efficace de la protéine de la revendication 7.

11. Utilisation des cellules de la revendication 5 pour la préparation d'une composition pour l'entretien ou le traitement des cellules nerveuses endommagées in vivo qui comprend une quantité efficace de cellules transgéniques compatibles capables d'exprimer une protéine MK.

Revendications pour les Etats contractants suivants : ES, GR

1. Procédé de production de protéine MK humaine pure ou d'une portion de celle-ci, qui comprend la transformation d'une cellule hôte par un ADN purifié et isolé, ayant la séquence de MK décrite dans la figure 1, codant pour une protéine MK humaine, ou une portion de celle-ci, qui code pour une protéine MK biologiquement active, et la culture de la cellule hôte dans des conditions qui permettent l'expression de l'ADN par la cellule hôte.

2. Procédé selon la revendication 1, dans lequel ledit ADN peut être hybridé à la séquence MK décrite dans la figure 1 dans des conditions hautement stringentes standards.

3. Procédé selon la revendication 1, dans lequel la protéine qu'il est possible d'obtenir comprend la séquence décrite dans la figure 1 et des homologues ou fragments de celle-ci qui conservent l'activité biologique de MK.

4. Procédé d'entretien ou d'activation de la croissance de cellules nerveuses in vitro qui comprend la culture des cellules en présence d'une quantité efficace d'une protéine qu'il est possible d'obtenir selon le procédé de l'une quelconque des revendications 1 à 3.

5. Procédé d'induction de la différentiation de cellules indifférenciées, qui comprend l'application aux cellules d'une quantité efficace d'une protéine qu'il est possible d'obtenir selon le procédé de l'une quelconque des revendications 1 à 3.

6. Vecteur d'expression comprenant un ADN purifié et isolé, ayant la séquence de MK décrite dans la figure 1, codant pour une protéine MK humaine, ou une portion de celle-ci, qui code pour une protéine MK biologiquement active.

7. Cellule transgénique comprenant un ADN purifié et isolé, ayant la séquence de MK décrite dans la figure 1, codant pour une protéine MK humaine, ou une portion de celle-ci, qui code pour une protéine MK biologiquement active.

8. Cellule selon la revendication 7, qui est déposée à l'American Type Culture Collection sous le numéro d'accession ATCC 68384.

9. Utilisation des cellules selon la revendication 7, pour la préparation d'une composition pour l'entretien ou le traitement des cellules nerveuses endommagées in vivo, qui comprend une quantité efficace de cellules transgéniques compatibles capables d'exprimer une protéine MK.

10. Procédé de production d'une composition thérapeutique comprenant le mélange d'une quantité efficace d'une protéine qu'il est possible d'obtenir selon le procédé de l'une quelconque des revendications 1 à 3 avec un véhicule

acceptable du point de vue pharmaceutique.

5

10

15

20

25

30

35

40

45

50

55

1 CGGGCGGAAGCAGCGGCGGGCAGCGAG

```
26   ATG CAG CAC CGA GGC TTC CTC CTC ACC CTC CTC GCC CTG CTG GCG CTC ACC
-22   M   Q   H   R   G   F   L   L   T   L   L   A   L   L   A   L   T

80   TCC GCG GTC GCC AAA AAG AAA GAT AAG GTG AAG AAG GGC CCG GGC AGC GAG
-4    S   A   V   A   K   K   K   D   K   V   K   K   G   P   G   S   E

134  TGC GCT GAG TGG GCC TGG GGG CCC TGC ACC CCC AGC AGC AAG GAT TGC GGC GTG
15    C   A   E   W   A   W   G   P   C   T   P   S   S   K   D   C   G   V

188  GGT TTC CGC GAG GGC ACC TGC GGG GCC CAG ACC CAG CGC ATC CGG TGC AGG GTG
33    G   F   R   E   G   T   C   G   A   Q   T   Q   R   I   R   C   R   V

242  CCC TGC AAC TGG AAG AAG GAG TTT GGA GCC GAC TGC AAG TAC AAG TTT GAG AAC
51    P   C   N   W   K   K   E   F   G   A   D   C   K   Y   K   F   E   N

296  TGG GGT GCG TGT GAT GGG GGC ACA GGC ACC AAA GTC CGC CAA GGC ACC CTG AAG
69    W   G   A   C   D   G   G   T   G   T   K   V   R   Q   G   T   L   K

350  AAG GCG CGC TAC AAT GCT CAG TGC CAG GAG ACC ATC CGC GTC ACC AAG CCC TGC
87    K   A   R   Y   N   A   Q   C   Q   E   T   I   R   V   T   K   P   C

404  ACC CCC AAG ACC AAA GCA AAG GCC AAG AAA GCC AAG GGG AAG GGA AAG GAC TAG
105   T   P   K   T   K   A   K   A   K   K   A   K   G   K   G   K   D   *

458  ACGCCAAGCCTGGATGCCAAGGAGCCCCTGGTGTCACATGGGGCCTGGCCACGCCCTCCTCTCCCAGGC
528  CCGAGATGTGACCCACCAGTGCCTTCTGTCTGCTCGTTAGCTTAATCAATCATGCCTTGTCCCT
598  CTCACTCCCCAGCCCCACCCCTAAGTGCCCAAAGTGGGAGGGACAAGGATTCTCGGGAAGCTTGAGCCT
668  CCCCCAAAGCAATGTGAGTCCCAGAGCCGCTTTGTTCTCCCACAATTCCATTACTAAGAAACACAT
738  CAAATAAACTGACTTTTTCCCCCCAATAAAGCTCTTCTTTTTAATATAAATAAAAAAAAA
```

FIG. 1

```
         1   G   K   K   E   K   P   E   K   K   V   K   K   S   D   C   G   E
HBNF     1  GGG AAG AAA GAG AAA CCA GAA AAA AAA GTG AAG AAG TCT GAC TGT GGA GAA
            XXX XXX XX  XX          X  XX      X       X   X   XX  XX  X   XX
MK       1  AAA AAG AAA GAT AAG GTG AAG AAG GGC GGC CCG GGG AGC GAG TGC GCT GAG
         1   K   K   K   D   K   V   K   K   G   G   P   G   S   E   C   A   E


        18   W   Q   W   S   V   C   V   P   T   S   G   D   C   G   L   G   T
HBNF    52  TGG CAG TGG AGT GTG TGT GTG CCC ACC AGT GGA GAC TGT GGG CTG GGC ACA
            XXX     XXX X      XX      XXX X X XX      XX  XX  XX  XX XX
MK      52  TGG GCC TGG GGG CCC TGC ACC CCC AGC AGC AAG GAT TGC GGC GTG GGT TTC
        18   W   A   W   G   P   C   T   P   S   S   K   D   C   G   V   G   F


        35   R   E   G   T   R   T   G   A   E   C   K   Q   T   M   K   T   Q
HBNF   103  CGG GAG GGC ACT CGG ACT GGA GCT GAG TGC AAG CAA ACC ATG AAG ACC CAG
            XX  XXX XXX XX                  XXX  X          X   XX  X
MK     103  CGC GAG GGC ACC  -   -   -   -   -  TGC GGG GCC CAG ACC CAG CGC ATC
        35   R   E   G   T    -   -   -   -   -   C   G   A   Q   T   Q   R   I


        52   R   C   K   I   P   C   N   W   K   K   Q   F   G   A   E   C   K
HBNF   154  AGA TGT AAG ATC CCC TGC AAC TGG AAG AAG CAA TTT GGC GCG GAG TGC AAA
             X  XX  X  X   X  XXX XXX XXX XXX XXX XXX  X  XXX XX  XX  XX  XXX XX
MK     139  CGG TGC AGG GTG CCC TGC AAC TGG AAG AAG GAG TTT GGA GCC GAC TGC AAG
        47   R   C   R   V   P   C   N   W   K   K   E   F   G   A   D   C   K
```

FIG.2

```
         69    Y   Q   F   Q   A   W   G   E   C   D   L   N   T   A   L   K   T
HBNF 205      TAC CAG TTC CAG GCC TGG GGA GAA TGT GAC CTG AAC ACA GCC CTG AAG ACC
              XXX  XX  XX      XX    X XXX  XX   X XXX  XX       X   X XXX X X      XX       X
MK   190      TAC AAG TTT GAG AAC TGG GGT GCG TGT GAT GGG GGC ACA GGC ACC AAA GTC
         64    Y   K   F   E   N   W   G   A   C   D   G   G   T   G   T   K   V


         86    R   T   G   S   L   K   R   A   L   H   N   A   E   C   Q   K   T
HBNF 256      AGA ACT GGA AGT CTG AAG CGA GCC CTG CAC AAT GCC GAA TGC CAG AAG ACT
                X        XX  X XXX XXX       XX   X      XX XXX  XX   X XXX XXX  XX  XX
MK   241      CGC CAA GGC ACC CTG AAG AAG GCG CGC TAC AAT GCT CAG TGC CAG GAG ACC
         81    R   Q   G   T   L   K   K   A   R   Y   N   A   Q   C   Q   E   T


        103    V   T   I   S   K   P   C   G   K   L   T   K   P   K   P   Q   A
HBNF 307      GTC ACC ATC TCC AAG CCC TGT GGC AAA CTG ACC AAG CCC AAA CCT CAA GCA
                   XX   X  XX  XX XXX XXX  XX       X       X XXX  XX   X  XX   X   XX  XX
MK   292      ATC CGC GTC ACC AAG CCC TGC ACC CCC AAG ACC AAA GCA AAG GCC AAA GCC
         98    I   R   V   T   K   P   C   T   P   K   T   K   A   K   A   K   A


        120    E   S   K   K   K   K   K   E   G   K   K   Q   E   K   M   L   D
HBNF 358      GAA TCT AAG AAG AAG AAA AAG GAA GGC AAG AAA CAG GAG AAG ATG CTG GAT
                X       X XXX      XX  X   X
MK   343      AAG AAA GGG AAG GGA AAG GAC TAG
        115    K   K   G   K   G   K   D   X


        137    X
HBNF 409      TAA
```

FIG. 2 (cont.)

```
        1  K   K   K   E   K   V   K   K   G   -   -   -   S   E   C   S   E
MOU     1 AAA AAA AAA GAG AAG GTG AAG AAG GGC  -   -   -  AGC GAG TGT TCG GAG
              x       x                                           x   x   x
HUM     1 AAA AAG AAA GAT AAG GTG AAG AAG GGC GGC CCG GGG AGC GAG TGC GCT GAG
        1  K   K   K   D   K   V   K   K   G   P   G   S   E   C   A   E


       15  V   P   V   G   P   C   T   P   S   S   K   D   C   G   H   G   F
MOU    43 TGG ACC TGG GGG CCC TGC ACC CCC AGC AGC AAG GAC TGC GGC ATG GGC TTC
              x                                       x       x       x
HUM    52 TGG GCC TGG GGG CCC TGC ACC CCC AGC AGC AAG GAT TGC GGC GTG GGT TTC
       18  V   A   V   G   P   C   T   P   S   S   K   D   C   G   V   G   F


       32  R   E   G   T   C   G   A   Q   T   Q   R   V   H   C   K   V   P
MOU    94 CGC GAG GGT ACC TGT GGG GCC CAG ACC CAG CGC GTC CAT TGC AAG GTG CCC
                  x       x                           x   xx      x
HUM   103 CGC GAG GGC ACC TGC GGG GCC CAG ACC CAG CGC ATC CGG TGC AGG GTG CCC
       35  R   E   G   T   C   G   A   Q   T   Q   R   I   C   R   V   P


       49  C   N   V   K   K   E   F   G   A   D   C   K   Y   K   F   E   S
MOU   145 TGC AAC TGG AAG AAG GAA TTT GGA GCC GAC TGC AAA TAC AAG TTT GAG AGC
                              x                   x                       x
HUM   154 TGC AAC TGG AAG AAG GAG TTT GGA GCC GAC TGC AAG TAC AAG TTT GAG AAC
       52  C   N   V   K   K   E   F   G   A   D   C   K   Y   K   F   E   N
          _____>


       66  V   G   A   C   D   G   S   T   G   T   K   A   R   Q   G   T   L
MOU   196 TGG GGG GCG TGT GAT GGG AGC ACT GGC ACC AAA GCC CGC CAA GGG ACC CTG
                  x               x   x           x           x
HUM   205 TGG GGT GCG TGT GAT GGG GGC ACA GGC ACC AAA GTC CGC CAA GGC ACC CTG
       69  V   G   A   C   D   G   G   T   G   T   K   V   R   Q   G   T   L


       83  K   K   A   R   Y   T   A   Q   C   Q   E   T   I   R   V   T   K
MOU   247 AAG AAG GCG CGG TAC ACT GCC CAG TGC CAG GAG ACC ATC CGC GTG ACT AAG
                          x       x   x                           x   x
HUM   256 AAG AAG GCG CGC TAC AAT GCT CAG TGC CAG GAG ACC ATC CGC GTC ACC AAG
       86  K   K   A   R   Y   N   A   Q   C   Q   E   T   I   R   V   T   K
                      <_____


      100  P   C   T   S   K   T   K   S   K   T   K   A   K   K   G   K   G
MOU   298 CCC TGC ACC TCC AAG ACC AAG TCA AAG ACC AAA GCC AAG AAA GGA AAA GGA
                      x               x   x       x                   x   x
HUM   307 CCC TGC ACC CCC AAG ACC AAA GCA AAG GCC AAA GCC AAG AAA GGG AAG GGA
      103  P   C   T   P   K   T   K   A   K   A   K   K   G   K   G


      117  K   D   x
MOU   349 AAG GAC TAG

HUM   358 AAG GAC TAG
      120  K   D   x
```

FIG. 3

FIG. 4

FIG. 5A

FIG. 5B

FIG. 5C

FIG. 5D

FIG. 6

FIG. 7

RA (µM)   C   0.01   0.05   0.1   0.5   1   5   10

Actin

HBNF

MK

FIG. 8A

FIG. 8B

THIS PAGE BLANK (USPTO)